"what kind of connection is this PBR to VNTA or are they the same? "
... Okay i'll try to answer best i can.
what kind of connection between the two companies?
The two companies recently signed an Official Letter of Intent to Collaborate, which confirmed Prime Bioresearch's intent to enter a full collaboration agreement with Ventana … Janne Christensen, President for Ventana, said, "By collaborating with Prime Bioresearch, we expect to accelerate the development of our proprietary Anti-Obesity Chewing Gum, which will bring us closer to our goal of out-licensing it to Big Pharma and reaping lucrative royalty payments."... read full story ===============================
are they the same?
Well I don't know if they are the same, but there are many similarities between the two companies: =============================== STRATEGIC PARTNERS PrimeBio has strategic partners, networks, and collaborations with companies, laboratories, CRO's, universities, and big pharma around the world, including in the UK, USA, India, China, Canada, France, Swizerland, Spain, Greece, India, and Scandinavia. ---------------------------------------------------------------- Alliances Ventana Biotech Inc has strategic partners, network, and collaborations with companies, laboratories, CRO's, universities, and pharma’s around the world, including in the UK, USA, India, China, Canada, France, Swizerland, Spain and Scandinavia.
=============================== almost identical comments can be found in two places:
in November 2008, the Issuer changed its business operations to pursue opportunities in the bio-medical industry through the purchase of the rights, title and interest in a novel treatment for obesity, an appetite suppressing chewing gum.
As of the date of this Information Statement, the Issuer is a biotech company with a sole focus on identifying, evaluating, acquiring, developing and partnering to achieve commercialization of intellectual property in the area of drug candidates for personalized medicine.
The Issuer has primarily targeted areas of anti-obesity and related illnesses. The Issuer believes that obesity is quickly becoming one of the largest health issues facing the Western world. Moreover, obesity leads to cardiovascular diseases, type-2 diabetes and a number of other lifestyle-induced disorders. Therefore, the Issuer is creating a team of experts with combined experience in patent law and medical research complemented by an advisory board comprised of international scientists.
The Issuer believes that the ultimate user of the appetite suppressing chewing gum can control his or her appetite efficiently without taking an ordinary drug. The appetite suppressing chewing gum is to be taken about thirty to sixty minutes prior to main meals, and it ensures that the user feels fuller quicker. It uses a hormone which is the body’s own way of switching off appetite after a meal and has no side effects. The hormone sends a signal to the brain that the stomach is full. In addition to the anti-obesity chewing gum, other intellectual property acquisitions are pending with leading universities and institutions in Europe and India.
On December 22, 2008, the Issuer entered into a Letter-of-Intent with PE Consortium Ltd. (“PEC”), a UK based company engaged in outsourcing R&D work to 3rd party research facilities. The Issuer expects to reach a full collaboration agreement with PEC in early Q2. The Letter-of-Intent is attached as Exhibit A to this Disclosure Document PE Consortium LTD. As of the date of this Information Statement, the Issuer has received a letter of agreement dated December 22, 2008 from PE Consortium LTD. (“PEC”), pursuant to which PEC sets forth its intention to undertake the administration and project management of the outsourcing of the research and development work for the appetite suppressing chewing gum. These duties could also be extended to other therapeutic areas in accordance with the expertise and capabilities of PEC.
The Issuer believes that this should enable it to obtain additional licenses to projects from academic research institutes around the world. PEC is a company that specializes in assisting early stage developmental biotech discovery companies to outsource their research and development to India at a significantly reduced cost. PEC has been instrumental in specifically assisting United Kingdom biotech companies with outsourced research and development sources.
We expect revenues from licensing fees as well as up-front and milestone payments from follow-on and new targets made available to big pharmaceutical companies and/or biotech companies should enable the Issuer to fully self finance next year.
------------------------------------------------------ Prime Bioresearch HISTORY Prime Bioresearch was founded by Mr. Konstantinos Kardiasmenos The company will principally be based in London, Spain, Athens and Bangalore. Prime Bioresearch Limited ("Company" or "Prime Bioresearch") was incorporated in England and Wales on 14 th March 2005 under Company Number 5391288. The Company Secretary is Mr. Graham May, who is a U.K. lawyer based in London. The initial shareholder, with £100 in share capital and a transfer of the IP relating to six provisional Indian patent applications for drug targets in metabolic disorders, i.e. Type 2-Diabetes and obesity, was Metra International Investments Limited ("Metra"), which operates as a trust company. On 1 st October 2005 Metra settled all of its shares in Prime Bioresearch into a declaration of trust with the beneficiaries of the trust to be scientific research objectives, and more specifically the following: 1. The creation of scientific laboratories and facilities in Bangalore, India, Copenhagen, Denmark, London, Oxford and Cambridge, England to research into drugs for metabolic disorders; 2. The education of young scientists and management and employees of any Research Company in life sciences required for research into metabolic disorders; 3. The communication and international exchange of information between research laboratories, universities, industry, governmental institutions and professionals working in the field of metabolic disorders;
MISSION
Prime Bioresearch is a drug target acquisition and development company with the aim of being the expert in identifying, evaluating and acquiring pioneering innovative research patents for subsequent research and transfer to other biotech companies and/or Big Pharma.
We focus on potential blockbuster drugs in large and growing markets, including lifestyle induced diseases. Our focus is on primary care drugs for the prevention and treatment of human diseases. Prime Bio focuses on six indication areas using our proprietary methodology for patent protection and drug development: Metabolic Disorders (Obesity and Diabetes-2), Cancer (prostate and breast cancer), Inflammatory diseases (arthritis, bowel diseases), Cardiovascular (anti-atherosclerotic and anti-inflammatory), Eye disorders, and Sleep disorders.
Prime Bioresearch runs a lean as well as cost- and time efficient drug development engine through the use of outsourcing and strategic partnerships. We aim for early partnerships to share costs, and research results.
Prime Bioresearch creates value through being industrious and systematic. We operate on the prime spot of value creation between existing patents phase III clinical studies.
Our mission is to make drugs available to the public at a faster rate. ---------- take care, sam
News 
Market Data 
Discover 
AI
